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Abstract
Ethosuximide is a medication used to treat seizure disorders in humans, and we previously demonstrated that ethosuximide
can delay age-related changes and extend the lifespan of the nematode Caenorhabditis elegans. The mechanism of action of
ethosuximide in lifespan extension is unknown, and elucidating how ethosuximide functions is important for defining
endogenous processes that influence lifespan and for exploring the potential of ethosuximide as a therapeutic for age-related
diseases. To identify genes that mediate the activity of ethosuximide, we conducted a genetic screen and identified mutations
in two genes, che-3 and osm-3, that cause resistance to ethosuximide-mediated toxicity. Mutations in che-3 and osm-3 cause
defects in overlapping sets of chemosensory neurons, resulting in defective chemosensation and an extended lifespan. These
findings suggest that ethosuximide extends lifespan by inhibiting the function of specific chemosensory neurons. This model
is supported by the observation that ethosuximide-treated animals displayed numerous phenotypic similarities with mutants
that have chemosensory defects, indicating that ethosuximide inhibits chemosensory function. Furthermore, ethosuximide
extends lifespan by inhibiting chemosensation, since the long-lived osm-3 mutants were resistant to the lifespan extension
caused by ethosuximide. These studies demonstrate a novel mechanism of action for a lifespan-extending drug and indicate
that sensory perception has a critical role in controlling lifespan. Sensory perception also influences the lifespan of Drosophila,
suggesting that sensory perception has an evolutionarily conserved role in lifespan control. These studies highlight the
potential of ethosuximide and related drugs that modulate sensory perception to extend lifespan in diverse animals.
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Introduction
Pharmacological compounds that extend lifespan could delay
the progression of age-related degenerative changes and age-
related illnesses such as Alzheimer’s disease and cardiovascular
disease. In addition, the characterization of drugs that extend
lifespan can elucidate endogenous mechanisms involved in lifespan
determination, since the targets of these drugs are likely to
influence normal aging. The short lifespan and rapid aging of
invertebrates makes them powerful models for the identification of
drugs that extend lifespan and for the characterization of the
mechanism of action of these drugs [1–3]. The free-living soil
nematode Caenorhabditis elegans has been a leading system for
studying genetic and pharmacologic influences on lifespan. Four
categories of compounds have been reported to extend C. elegans
lifespan: a variety of antioxidant compounds [4–9]; complex
mixtures derived from plants [10,11]; resveratrol, a potential
modulator of Sir2 activity [12,13]; and medications such as
heterocyclic anticonvulsant medications that may act by affecting
neural activity [14–17]. Compounds that extend the lifespan of
vertebrates have not been well characterized. However, a recent
report showing that resveratrol can extend the lifespan of a short-
lived fish suggests that compounds that extend invertebrate
lifespan may be relevant to vertebrate biology [18].
By screening 19 drugs from different structural and functional
classes that are FDA-approved for human use, Evason et al. (2005)
discovered that ethosuximide can extend the lifespan of C. elegans
[14]. Ethosuximide is a small, heterocyclic ring compound of the
succinimde class that is approved for human use as an
anticonvulsant [19]. Trimethadione is a structurally related
anticonvulsant that is a member of the oxazolidinedione class,
and trimethadione also extends C. elegans lifespan [14]. Ethosux-
imide is commonly used in clinical practice whereas trimethadione
is rarely used due to the potential for adverse side effects.
Ethosuximide extended the mean adult lifespan of wild-type
animals grown on agar dishes by 17% [14]. The effect is dose
dependent, and at high doses ethosuximide causes toxicity. In
addition, ethosuximide extends the span of time that animals
display fast body movement and pharyngeal pumping, demon-
strating that ethosuximide delays age-related functional declines in
addition to extending lifespan. Ethosuximide has been shown to
affect the activity of multiple ion channels in vertebrate cultured
cells, including T-type calcium channels [20–22]. The relationship
between these activities in cultured cells and the anticonvulsant
activity in whole animals has yet to be defined fully. Furthermore,
the mechanism of action for lifespan extension in worms is not well
characterized.
To elucidate the mechanism of action of ethosuximide, we
conducted a genetic screen for mutations that cause resistance to
the drug. Screening for drug resistance is a well-established
approach in C. elegans [23]. A mutation can cause resistance to a
drug for several different reasons such as altering the molecular
PLoS Genetics | www.plosgenetics.org 1 October 2008 | Volume 4 | Issue 10 | e1000230target of the drug, the cellular target of the drug, or the metabolism
of the drug. An example of resistant mutants that identified the
molecular target include the ivermectin resistant locus avr-15, which
encodes a glutamate gated chloride channel that binds ivermectin
[24] and the a-amanitin resistant locus ama-1, which encodes a
RNA polymerase that binds a-amanatin [25,26]. An example of a
gene that affects drug metabolism and was identified in a screen for
drug resistant mutants is nrf-6, which functions in intestinal cells to
promote fluoxetine sensitivity [27].
Here we analyze the mechanism of action of ethosuximide in
lifespan extension and show that it is related to the activity of
chemosensory neurons, indicating that these neurons are the cellular
target of ethosuximide in lifespan extension. C. elegans and other
animals live in complex environments that can change rapidly, and
therefore these animals have evolved the ability to respond quickly to
changing conditions. The ability to perceive chemosensory cues and
mount behavioral responses enables an animal to adjust to
environmental changes. C. elegans uses ciliated chemosensory neurons
located in the anterior and posterior of the animal to respond to
numerous soluble and volatile cues [28–30]. Mutations that cause
defects in cilia structure or sensory signaling within chemosensory
neurons disrupt chemotaxis towards soluble and volatile chemicals
[29–31]. These chemosensory neurons also influence adult lifespan,
sincemutations that cause defects in the structureof cilia or mutations
that cause defects in sensory signaling can extend lifespan [32,33].
Furthermore, laser ablation of the chemosensory neurons ASI, AWA,
and AWC, separately or together, can increase adult lifespan [34].
These results indicate that the activity of certain chemosensory
n e u r o n sp r o m o t e sas h o r tl i f e s p a n .
To characterize the mechanism of action of ethosuximide, we
conducted a genetic screen and identified mutations in two genes,
che-3 and osm-3, that cause resistance to ethosuximide-mediated
toxicity. Mutations in che-3 and osm-3 cause defects in overlapping
sets of chemosensory neurons and can extend lifespan [32]. These
findings indicate that ethosuximide extends lifespan by inhibiting a
subset of chemosensory neurons. Here we present results that
strongly support this model. Ethosuximide treated wild-type
animals displayed numerous phenotypic similarities with mutants
that have chemosensory defects, indicating that ethosuximide
inhibits chemosensory function. Importantly, the long-lived osm-3
mutants did not respond to lifespan extending doses of
ethosuximide. These studies demonstrate a novel mechanism of
action for a lifespan extending drug and demonstrate the potential
of pharmacologically targeting the sensory system as a means to
extend animal lifespan.
Results
The C. elegans T-type Calcium Channel, CCA-1, Is Not
Required for Ethosuximide to Extend Lifespan or
Stimulate Egg-Laying
Studies using vertebrate cultured cells have led to the proposal
that T-type calcium channels may be the molecular target of
ethosuximide in controlling seizures [20,22,35]. To determine if
ethosuximide inhibits T-type calcium channels to extend lifespan,
we analyzed a null mutation in the gene encoding the C. elegans
orthologue of the mammalian T-type calcium channel, cca-1(gk30)
[36,37]. If ethosuximide inhibits T-type calcium channels to
extend lifespan, then we predict that (1) a cca-1 loss-of-function
mutant will be long-lived and (2) a cca-1 loss-of-function mutant
will not respond to the lifespan extension caused by ethosuximide.
cca-1(gk30) mutants displayed a mean adult lifespan of 15.2 days,
which was not significantly different from the 16.1 day mean adult
lifespan of wild-type animals (Figure 1A). cca-1(gk30) hermaphro-
dites treated with ethosuximide displayed a robust lifespan
extension, indicating that ethosuximide does not require T-type
calcium channels to extend C. elegans lifespan (Figure 1A).
In addition to extending lifespan, ethosuximide also stimulates
the rate of egg-laying [14]. To determine if ethosuximide requires
T-type calcium channels to stimulate egg-laying, we utilized a well-
described assay that involves counting the eggs laid by a young
adult hermaphrodite that is transferred from a Petri dish with
abundant food to M9 liquid culture with no food [38]. We
analyzed a second putative cca-1 null allele, cca-1(ad1650) [36,37].
Wild-type and cca-1(ad1650) hermaphrodites transferred to M9
buffer laid zero eggs in 90 minutes (Figure 1B), demonstrating that
egg-laying is strongly inhibited by these conditions. Wild-type and
cca-1(ad1650) hermaphrodites displayed a similar, dose-dependent
increase in egg-laying in response to ethosuximide (Figure 1B),
indicating that T-type calcium channels are not required for
ethosuximide stimulated egg-laying. Collectively, these results
suggest that ethosuximide modulates lifespan and egg-laying in C.
elegans by acting on molecular targets distinct from the T-type
calcium channel CCA-1.
A Genetic Screen for Ethosuximide Resistant Mutants
Implicates Ciliated Neuron Function in Ethosuximide
Sensitivity
The identification and characterization of mutants that are
resistant to the activity of a drug has been a useful approach for
elucidating the mechanism of drugs in C. elegans [24,39–41]. The
analysis of candidate genes, including cca-1 and genes that
influence longevity [14], did not clearly identify the target of
ethosuximide. Therefore, we conducted a genetic screen for
mutations that cause resistance to ethosuximide. To identify a
phenotype for conducting a genetic screen that is more suitable
than lifespan, we performed a dose response analysis. The optimal
dosage for lifespan extension by ethosuximide was 2–4 mg/ml in
the culture media [14]. Concentrations of ethosuximide greater
than 4 mg/ml caused dose dependent larval lethality (data not
Author Summary
Aging is a major factor that contributes to disease and
disability in humans, but no medicines have been
demonstrated to delay human aging. We previously
conducted a screen for FDA-approved drugs that can
extend the lifespan of the nematode worm C. elegans,
resulting in the identification of ethosuximide, a medicine
used to treat epilepsy. To elucidate the mechanism of
action of ethosuximide in lifespan extension, we conduct-
ed a genetic screen for C. elegans mutations that cause
resistance to ethosuximide. Here, we describe the identi-
fication of genes that are critical for ethosuximide
sensitivity. These genes are necessary for the function of
neurons that mediate sensory perception. Furthermore,
ethosuximide treatment caused defects in sensory per-
ception. These results indicate that ethosuximide affects
lifespan by inhibiting neurons that function in the
perception of sensory cues. These studies highlight the
importance of sensory neurons in lifespan determination
and demonstrate that a drug can act on specific cells
within the nervous system to extend lifespan. Sensory
perception also modulates Drosophila lifespan, suggesting
this is an evolutionarily conserved relationship. Our results
indicate that sensory perception may be a promising
target for pharmacological extension of lifespan in a
variety of animals.
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was 12 mg/ml ethosuximide. The larval lethal phenotype is ideal
for the isolation of resistant mutants, because it is possible to screen
large numbers of mutant animals for survival in 12 mg/ml
ethosuximide. We mutagenized wild-type animals with EMS or
ENU, screened approximately 200,000 haploid genomes for
mutants that survived when cultured on 12 mg/ml ethosuximide,
and isolated 48 mutants. Forty-two mutant strains were success-
fully backcrossed to wild-type animals, indicating that ethosuxi-
mide resistance in these strains is caused by a mutation in one
gene. In all cases the mutant strains displayed partially penetrant
survival in 12 mg/ml ethosuximide (Table 1 and data not shown),
indicating that these mutations cause a shift in the dose response to
ethosuximide and do not abrogate sensitivity to this drug. Here we
describe six of these mutations that represent two complementa-
tion groups.
To characterize the mutations that cause ethosuximide
resistance, we positioned these mutations on the C. elegans genetic
and physical maps. The mutations am178, am165, and am162
exhibited tight linkage to a single nucleotide polymorphism (SNP)
marker positioned at the center of Chromosome I (see Materials and
Methods). Three-factor mapping positioned am178 between dpy-5
and unc-75 on Chromosome I (Figure 2). High resolution mapping
positioned am178 between SNP markers uCE1-952 and
snp_T01G9[1], a ,250 kB interval on Chromosome I (Figure 2).
To identify the gene affected by am178, we analyzed candidate
genes in the interval by measuring the ability of existing mutations
to cause resistance to ethosuximide lethality. To quantitatively
assess the drug resistance of a mutant, we exposed embryos to
12 mg/ml ethosuximide for five to six days and measured the
number of surviving animals that developed past the L1 larval
stage. che-3(e1124) mutants displayed resistance to 12 mg/ml
ethosuximide that was 31 percent penetrant (Table 1). Further-
more, che-3(e1124) failed to complement am178 for resistance to
ethosuximide, indicating that am178 is a mutation in che-3 (see
Materials and Methods). To test the prediction that the am178
mutation reduces the activity of the che-3 gene, we generated
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Figure 1. Ethosuximide treatment extended lifespan and
stimulated egg laying in cca-1 null-mutants. (A) Ethosuximide
extended the lifespan of cca-1(gk30) mutants. Wild-type or cca-1(gk30)
hermaphrodites were cultured with 0 mg/ml or 4 mg/ml ethosuximide
(+ETH 4) from conception until death. The mean lifespans in days6SD
for WT, WT+ETH 4, cca-1, and cca-1+ETH 4 were 16.163.3 (n=110),
19.564.8 (n=120), 15.264.9 (n=140), and 20.866.6 (n=110), respec-
tively. The differences in mean lifespan of WT compared to WT+ETH 4
and cca-1 compared to cca-1+ETH 4 were statistically significant,
p,0.0001 (Student T-test). (B) cca-1 mutants responded to ethosuxi-
mide stimulated egg-laying. The mean number of eggs laid6SD by
wild-type animals (blue circles) was 0.060.0, 0.762.2, 2.062.5, and
6.865.2 for ethosuximide concentrations of 0, 4, 8, and 12 mg/ml,
respectively. The mean number of eggs laid6SD by cca-1(ad1650)
mutant animals (red squares) was 0.060.0, 0.2561.0, 2.763.1 and
8.065.6 for ethosuximide concentrations of 0, 4, 8, and 12 mg/ml,
respectively. n.23 for all trials. Differences in egg-laying between WT
and cca-1 at ethosuximide concentrations of 0, 4, 8 and 12 mg/ml were
not statistically significant, p.0.05 (Student T-test).
doi:10.1371/journal.pgen.1000230.g001
Table 1. Mutants with defects in cilia structure were resistant
to ethosuximide toxicity.
Genotype
Amphid
Dye-Filling
‘
Percent Ethosuximide
Resistant
# (n)
WT + 0 (783)
che-3(am178) + 30.1 (199)
che-3(am165) Dyf 26.1 (413)
che-3(am162) Dyf 10.2 (525)
che-3(e1124) Dyf
{ 30.8 (668)*
osm-3(am161) Dyf 43.4 (426)
osm-3(am177) Dyf 41.1 (451)
osm-3(am172) Dyf ND
osm-3(p802) Dyf
{ 79.6 (621)
che-13(p1805) Dyf
{ 62.0 (756)
daf-10(e1387) Dyf
{ 22.6 (729)
osm-5(p813) Dyf
{ 36.6 (209)*
‘Animals cultured at 20uC were classified as normal (+) or defective (Dyf) for
amphid neuron dye filling (see Materials and Methods).
#Experiments were done with 12 mg/ml ethosuximide. The differences in
percent resistance between che-3 alleles were not statistically significant
except that che-3(am162) was significantly different from che-3(am178), che-
3(am165) and che-3(e1124) (p,0.0001). The differences in percent resistance
between osm-3 alleles were not statistically significant except that osm-
3(p802) was significantly different from osm-3(am161) and osm-3(am177)
(p,0.0001).
{The dye-filling phenotype of these mutants was described previously [28].
*These values may underestimate the fraction of animals that were resistant to
ethosuximide, since we observed multiple animals that were mature,
indicating they were ethosuximide resistant, but they were desiccated on the
side of the dish and not included in the data. We have observed that mutants
with severe chemotaxis defects have a propensity to leave the agar surface.
doi:10.1371/journal.pgen.1000230.t001
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fosmid clone that included the che-3 gene. This wild-type copy of
the che-3 gene rescued the am178 mutant phenotype (see Materials
and Methods). To identify the molecular lesion, we determined the
DNA sequence of the predicted che-3 exons and splice junctions
using DNA from am178 mutants. We identified a single base
change that affects the splice junction following exon 9 (the 59
splice site was changed from GTATG in wild-type to GTATA in
am178 mutants). Analysis of transcripts demonstrated that am178
mutants produce an aberrantly spliced che-3 mRNA that is
predicted to encode a truncated CHE-3 protein, suggesting that
am178 is a loss-of-function mutation of the che-3 gene.
che-3 encodes a cytoplasmic dynein heavy-chain [42]. Dynein is
a component of the intraflagellar transport (IFT) machinery, and
this machinery builds and maintains the structure of ciliated
neurons in C. elegans. Mutations that disrupt IFT components, such
as CHE-3 dynein, result in defects in the structure of ciliated
neurons [43]. C. elegans contains 60 ciliated neurons, and these
neurons function in the perception of chemical and mechanical
cues [28–31,44]. The most extensively characterized ciliated
neurons are present in the amphid organ, a bilaterally symmetrical
neural structure located in the anterior of the animal. Some
amphid neurons have ciliated dendrites that are exposed to the
external environment, since they extend through a channel in the
cuticle [28,45]. Since these neurons are exposed to the
environment, treating animals with lipophilic dyes such as DiO
specifically stains these neurons (Figure 3A)[28,46]. Mutants with
severe defects in the structure of these neurons display no staining,
a phenotype referred to as dye-filling defective (Dyf) (Figure 3D)
[28,31]. Many che-3 mutations cause a robust Dyf phenotype [42].
To characterize che-3(am178) and two candidate che-3 alleles
that were positioned near the center of Chromosome I, am162 and
am165, we performed the dye-filling assay. am162 and am165 both
caused a Dyf phenotype (Table 1), and both mutations failed to
complement che-3(e1124) for dye-filling defects (Materials and
Methods), indicating that am162 and am165 are alleles of che-3.
che-3(am178) mutants cultured at 20uC displayed dye-filling that
was not significantly different from wild-type (Table 1, Table 2 and
Figure 3B). However, che-3(am178) mutants cultured at 27uC
displayed a highly penetrant dye-filling defective phenotype
(Table 2), indicating that the am178 mutation partially reduces
the activity of the che-3 gene at the permissive temperature of 20uC
and strongly reduces the activity of the che-3 gene at the restrictive
temperature of 27uC. To determine the temporal requirement for
che-3 gene activity, we cultured hermaphrodites at 20uC until the
L4 stage of development and then shifted the animals to 27uC for
24 hours before scoring DiO staining. Using this regimen che-
3(am178) mutants displayed a significant defect in DiO staining,
indicating that che-3 function is necessary after the L4 stage to
maintain cilia structure (Table 2). The findings that che-3(am178)
mutants cultured at 20uC displayed robust resistance to ethosux-
imide toxicity but did not display dye-filling defects indicate that
gross morphological defects in amphid neuron structure are not
required for che-3 mutants to be resistant to ethosuximide.
Three Mutations that Cause Ethosuximide Resistance
Affect the osm-3 Gene that is Necessary for Ciliated
Neuron Structure
Since che-3 mutations cause both ethosuximide resistance and
DiO staining defects, we characterized dye-staining of the
remaining ethosuximide resistant mutants. Three mutations that
exhibited tightest linkage to a marker positioned at 23.7 on
Chromosome IV, am161, am172 and am177, caused defects in DiO
dpy-5
unc-75
2.43 2.7
 non-Dpy
 non-Unc
2.45 9.3  0
55  1  0  0
 71  1  0 0
uCE-952
snp_T01G9[1] 
uCE-955
Ethosuximide
Resistant
Recombinants
am178
che-3
Figure 2. Positioning the am178 mutation. The horizontal line
represents a portion of Chromosome I. Genes that can be mutated to
cause visible phenotypes and SNP markers are shown above; map units
are shown below. From dpy-5 am178/CB4856 hermaphrodites, we
selected 56 ethosuximide resistant, non-Dpy self-progeny. From am178
unc-75/CB4856 hermaphrodites, we selected 72 ethosuximide resistant,
non-Unc self-progeny. An analysis of SNP markers in these strains
positioned the recombination events in the intervals shown below. The
double-headed arrow indicates a 250 kBp interval between the SNP
markers uCE-952 and snp_T01G9[1] that contains am178.
doi:10.1371/journal.pgen.1000230.g002
WT che-3(am178)
WT + ETH 4 osm-3(p802)
A B
C D
Figure 3. Ethosuximide treated animals and che-3(am178)
mutants cultured at 20uC did not display dye-filling defects.
Animals were incubated in the lipophilic dye DiO and observed using
fluorescence microscopy at 2006 magnification. Each panel illustrates
the anterior tip of the animal (top) to the base of the bi-lobed pharynx
(bottom). DiO stains amphid neuron processes (arrows) and cell bodies
(arrowheads). Wild-type (WT) animals displayed robust staining that was
not affected by treatment with 4 mg/ml ethosuximide (WT+ETH4). che-
3(am178) mutants cultured at 20uC displayed robust staining, whereas
osm-3(p802) mutants displayed no detectable staining (the Dyf
phenotype).
doi:10.1371/journal.pgen.1000230.g003
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osm-3 alleles because osm-3 is located at 22.2 on Chromosome IV
and can be mutated to produce defective DiO staining (Figure 3D).
am161, am172, and am177 each failed to complement the osm-3
reference allele p802 for DiO staining defects, suggesting that each
mutation affects the osm-3 gene (see Materials and Methods).
Furthermore, the osm-3(p802) mutation caused 80 percent
resistance to ethosuximide (Table 1), consistent with the model
that am161, am172, and am177 are osm-3 alleles.
Like the CHE-3 dynein, the OSM-3 kinesin is a component of
the IFT machinery that is essential for the formation of ciliated
nerve endings. The OSM-3 kinesin has been divided into four
domains: motor, neck, rod, and tail (Figure 4) [47]. Previous
molecular genetic studies identified two missense mutations that
affect the motor region and one missense mutation that affects the
rod region. To identify molecular lesions in the new osm-3 alleles,
we determined the DNA sequence of osm-3 exons using DNA from
am177 mutants. We identified a single base change in the coding
region of the am177 allele; this missense mutation changes codon
329 from asparagine to histidine (Figure 4). The am177 mutation
in the osm-3 gene is distinct from previously characterized missense
mutations and affects the neck region, thus identifying a residue in
the neck region that is critical for protein function (Figure 4).
Chemosensory Neurons Are Necessary to Mediate
Sensitivity to Ethosuximide
The demonstration that che-3 and osm-3 are necessary for
sensitivity to ethosuximide-induced lethality suggests that the
function of ciliated neurons is necessary to mediate the toxic effects
of ethosuximide. To investigate this model, we exploited the well-
characterized collection of mutations that affect ciliated neurons
[28,31]. che-13, daf-10 and osm-5 encode IFT components, and
loss-of-function mutations of these genes cause robust defects in
DiO staining. Loss-of-function mutations of che-13, daf-10 and osm-
5 caused significant ethosuximide resistance of 62 percent, 23
percent, and 37 percent, respectively (Table 1). These results
support the hypothesis that the function of ciliated neurons is
necessary to mediate the effects of ethosuximide.
We identified five different genes (che-3, osm-3, daf-10, osm-5, and
che-13) that influence ethosuximide toxicity. Because these genes
encode diverse protein products, it is unlikely that these proteins are
the direct molecular target of ethosuximide. However, these genes
are all required for the structure or function of ciliated neurons,
indicating that ciliated neurons may be an important cellular focus
of ethosuximide function. The che-3, che-13, daf-10, and osm-5 genes
are necessary for the structure or activity of all 60 ciliated neurons
[28]. By contrast, the osm-3 gene is necessary for only a subset of
ciliated neurons. osm-3 expression is restricted to amphid, phasmid
and inter labial neurons that function in chemosensation, and osm-3
loss-of-function mutants are specifically defective in behaviors
mediated by these neurons [28,48,49]. These observations define
a subset of chemosensory neurons that are defective in osm-3
mutants as critical for the response to ethosuximide toxicity.
osm-3 Mutants Responded to the Egg-Laying Stimulation
Caused by Serotonin and Ethosuximide, Indicating that
These Mutants Absorbed These Drugs
In principle, mutations that disrupt cilium structure could cause
resistance to ethosuximide toxicity because they affect the
molecular target, the cellular target or the metabolism of the
drug. Mutations that disrupt cilium structure prevent the lipophilic
dye DiO from staining the membranes of ciliated neurons. This
raises the possibility that these mutations also disrupt absorption of
water soluble drugs, such as ethosuximide [24]. If this were the
case then these mutants are predicted to be resistant to a wide
variety of drugs. To investigate this possibility, we analyzed
resistance to serotonin, a well-characterized compound that
stimulates egg-laying [38]. We compared the resistance of wild-
type hermaphrodites and osm-3(p802) mutants. osm-3(p802) has
been extensively characterized using behavioral assays and
electron microscopic analyses [28]. Genetic studies indicate that
osm-3(p802) is a strong loss-of-function mutation, and molecular
studies demonstrate that the allele contains a nonsense change at
codon 346 [47] (Figure 4). Our analysis also supports the
Table 2. The che-3(am178) mutation caused temperature-
sensitive defects in DiO staining of amphid neurons.
Genotype Temperature (uC)
‘ % Dyf N
WT 20 0 22
che-3(am178) 20 1.3 76
WT 27 0 47
che-3(am178) 27 93 121
WT 20R20 0 64
che-3(am178) 20R20 0 83
WT 20R27 0 51
che-3(am178) 20R27 44 72
‘For lines 1–4, hermaphrodites were cultured from conception to L4 at the
indicated temperature. For lines 5–8, hermaphrodites were cultured from
conception to L4 at 20uC and then shifted to the indicated temperature for
approximately 24 hours.
doi:10.1371/journal.pgen.1000230.t002
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Figure 4. am177 is a missense mutation of osm-3. (A) A schematic
of the OSM-3 protein showing amino acid numbers (below) and four
functional regions: the motor (left diagonal lines), neck (shaded), rod
(open) and tail (right diagonal lines) [47]. The position of am177 and six
previously characterized mutations are shown above with the mutation
name and molecular change [47]. (B) The predicted amino acid
sequence of OSM-3 (M02B7.1B). The am177 mutation changes codon
329 from AAC (N) to CAC (H), affecting the neck region of the protein.
doi:10.1371/journal.pgen.1000230.g004
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since the osm-3(p802) mutation caused a significantly greater
resistance to ethosuximide toxicity than the newly isolated osm-
3(am177) and osm-3(am161) mutations. Wild-type animals and osm-
3(p802) mutants displayed similar sensitivity to the stimulation of
egg-laying caused by serotonin (Figure 5A). These results indicate
that entry of serotonin into the animal is normal in osm-3 mutants
despite the defects in cilium structure.
To directly investigate the absorption of ethosuximide by cilium
structure mutants, we analyzed a separate phenotype caused by
ethosuximide. If drug absorption is mediated by ciliated neurons,
then mutants with defective cilium structure are predicted to be
resistant to all the effects of ethosuximide. By contrast, if drug
absorption is not mediated by ciliated neurons, then mutants with
defective cilium structure are predicted to be sensitive to the effects
of ethosuximide mediated by non-ciliated cells. The ethosuximide
effect we chose to analyze is the stimulation of egg-laying, since we
previously showed this effect required the activity of non-ciliated
HSN neurons that innervate the egg laying muscles [14]. We chose
the osm-3(p802) mutant for these analyses because it has severe
defects in cilium structure and is highly resistant to ethosuximide
toxicity (Table 1). Wild-type and osm-3 hermaphrodites transferred
to M9 buffer laid an average of 0.17 and 0.29 eggs in 90 minutes,
respectively (Figure 5B). Wild-type and osm-3 hermaphrodites
displayed a similar, dose-dependent increase in the rate of egg-
laying in the presence of ethosuximide (Figure 5B), indicating that
ethosuximide stimulates egg-laying in these conditions. These
results demonstrate that osm-3 mutants have a normal response to
ethosuximide-stimulated egg-laying, indicating that the entry of
ethosuximide into the animal is normal in these mutants.
Mutations that Impair Ciliated Neurons and Treatment
with Ethosuximide Cause Similar Defects in Chemotaxis
Our findings suggest that ethosuximide affects the activity of
chemosensory neurons. To directly investigate this model, we
compared the effects of ethosuximide treatment and mutations
that cause defects in chemosensory neurons. Animals with defects
in amphid neurons resulting from mutations or physical ablation
do not respond properly to chemical cues from the environment
and display defective chemotaxis [28–31]. To analyze how
ethosuximide treatment affects chemotaxis, we measured chemo-
taxis towards the volatile odorant isoamyl alcohol which is
mediated by AWC amphid neurons [29]. Untreated wild-type
animals displayed a chemotaxis index towards isoamyl alcohol of
about 0.8, and ethosuximide treatment significantly reduced this to
about 0.3 (Figure 6A). This result indicates that ethosuximide
disrupts the activity of AWC amphid neurons, resulting in
defective chemotaxis.
To determine if ethosuximide treatment affects additional
amphid neurons, we analyzed chemotaxis of ethosuximide treated
animals to the volatile attractant diacetyl, an odorant detected by
AWA amphid neurons [29]. Ethosuximide treatment significantly
diminished chemotaxis toward diacetyl (Figure 6B), indicating that
ethosuximide disrupts the activity of AWA neurons. These results
suggest that treatment with ethosuximide disrupts multiple
chemosensory amphid neurons that mediate chemotaxis, including
AWC and AWA.
Ethosuximide Treatment Caused Daf-c and Daf-d
Phenotypes, Similar to Mutations that Disrupt
Chemosensory Function
Amphid neurons play important roles in the developmental
decision between forming an L3 larva that matures to a
reproductive adult or a dauer larva that persists until environ-
mental conditions improve. Laser ablation studies indicate that
specific chemosensory amphid neurons are necessary to inhibit
dauer formation (ASI, ADF, and ASG), and to promote dauer
formation (ASJ) [50,51]. Consistent with these observations,
mutations that cause defects in multiple chemosensory neurons
A
B
Figure 5. osm-3(p802) animals are sensitive to egg-laying
stimulated by serotonin and ethosuximide. (A) Gravid hermaph-
rodites were placed individually in M9 buffer containing the indicated
serotonin concentration, and the number of eggs laid in 90 minutes
was scored. The mean number of eggs laid6SD by wild-type animals
(blue circles) was 0.661.2, 1.461.8, 7.364.9, and 5.764.3 for serotonin
concentrations of 0, 1, 10, and 20 mM, respectively. The mean number
of eggs laid6SD by osm-3(p802) animals (red squares) was 0.661.7,
0.360.9, 4.863.5, and 7.163.4 for serotonin concentrations of 0, 1, 10,
and 20 mM, respectively. N.11 for all trials. At all serotonin
concentrations, differences in egg-laying between WT and osm-3 were
not statistically significant, p.0.05 (Student t-test). (B) Experiments with
ethosuximide were carried out as above with the indicated concentra-
tion of ethosuximide. The mean number of eggs laid6SD by wild-type
animals (blue circles) was 0.260.5, 1.161.4, 4.564.2, and 7.663.6 for
ethosuximide concentrations of 0, 4, 8, and 12 mg/ml, respectively. The
mean number of eggs laid6SD by osm-3 mutant animals (red squares)
was 0.360.8, 1.762.6, 6.064.3, and 9.662.8 for ethosuximide concen-
trations of 0, 4, 8, and 12 mg/ml, respectively. n=24 for all trials.
Differences in egg-laying between WT and osm-3 at ethosuximide
concentrations of 0, 4, and 8 were not statistically significant, p.0.05
(Student T-test). At 12 mg/ml ethosuximide, osm-3 animals laid
significantly more eggs than wild-type animals, p=0.03 (Student T-test).
doi:10.1371/journal.pgen.1000230.g005
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cause dauer defective (Daf-d) phenotypes or dauer constitutive
(Daf-c) phenotypes depending on the environmental conditions
[32,52–54]. To investigate the effects of ethosuximide on
chemosensory neuron activity, we analyzed the effects of
ethosuximide treatment on dauer formation in environmental
conditions previously described to cause Daf-d and Daf-c
phenotypes in animals with chemosensory neuron defects.
The combination of high temperature, high population density
and low food availability promotes the formation of dauer larvae
in wild-type animals [23]. Mutants with defects in chemosensory
neurons display a Daf-d phenotype in this combination of culture
conditions, indicating that these sensory neurons are necessary to
respond to these environmental cues and promote dauer larvae
formation [54]. To determine if ethosuximide treatment causes a
similar Daf-d phenotype, we analyzed animals cultured at the high
temperature of 25uC, at a high population density, and with low
food availability. The osm-3(p802) mutation significantly reduced
the average number of dauer larvae by 10-fold, from 250 to 26
(p,0.0001) (Table 3), consistent with previous observations [54].
Ethosuximide treatment of wild-type animals significantly reduced
the average number of dauer larvae by 16-fold, from 250 to 16
(p,0.0001) (Table 3). These results indicate that ethosuximide
inhibits chemosensory neurons that are necessary to promote
dauer larvae formation.
By contrast to the culture conditions described above, culturing
animals in low density populations with abundant food at the
extremely high temperature of 27uC reveals that chemosensory
neuron function is necessary to inhibit dauer formation [32,52].
To determine if ethosuximide treatment and mutations that
disrupt chemosensory neurons cause similar defects, we analyzed
dauer larvae formation at 27uC. The osm-3(p802) mutation
significantly increased the fraction of dauer larvae from 0 to 7
percent (Table 4). Ethosuximide treatment of wild-type animals
significantly increased the fraction of dauer larvae from 0 to 10
percent (p,0.0001) (Table 4), indicating that ethosuximide
treatment and an osm-3 mutation caused similar defects in the
ability to inhibit dauer formation. To investigate the relationship
between the dauer promoting effects of ethosuximide and the osm-
3(p802) mutation, we treated osm-3(p802) mutants with ethosux-
imide. Ethosuximide treatment did not enhance the dauer arrest
caused by osm-3(p802) (Table 4), suggesting that ethosuximide and
osm-3 mutations promote dauer arrest by a similar mechanism.
Collectively, these results indicate that ethosuximide treatment can
cause Daf-c and Daf-d phenotypes in specific environmental
conditions, and this result supports the model that ethosuximide
disrupts the activity of multiple chemosensory neurons.
Mutations that Impair Chemosensory Neurons and
Treatment with Ethosuximide Caused Similar Defects in
L1 Arrest
Insulin/IGF-1 signaling is a critical regulator of dauer formation
and an important modulator of adult lifespan [55–57]. daf-2
encodes a receptor tyrosine kinase similar to the insulin receptor
[56], and age-1 encodes a phosphatidylinositol-3-kinase that
functions downstream in the signaling pathway [58]. Loss-of-
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Figure 6. Ethosuximide disrupted chemotaxis toward the
volatile attractants isoamyl alcohol and diacetyl. Wild-type
animals grown from conception to adulthood on NGM plates
containing 2 mg/ml ethosuximide or no drug were transferred to the
center of a 10 cM chemotaxis plate containing 4 mg/ml of ethosuxi-
mide or no drug, respectively. A chemotaxis index (CI) to isoamyl
alcohol or diacetyl was determined. (A) Chemotaxis to isoamyl alcohol.
The mean CI6SD for untreated and ethosuximide treated animals was
0.860.2 and 0.360.2, respectively (p,0.0001, n=8) (Student T-test). (B)
Chemotaxis to diacetyl. The mean CI6SD for untreated and ethosux-
imide treated animals was 0.860.14 and 0.260.2, respectively
(p=0.0009, n=6) (Student T-test). Error bars represent standard error
of mean.
doi:10.1371/journal.pgen.1000230.g006
Table 3. Ethosuximide inhibited dauer formation in a high-
density, starved population at 25uC.
Genotype
Ethosuximide
(mg/ml)
Dauer6SD
(Number/Dish) N (Dishes)
WT 0 2506110 13
WT 4 16615*** 11
osm-3(p802) 02 6 627*** 10
***p,0.0001, comparisons are to WT with no drug treatment. p values
determined by Student T-test.
doi:10.1371/journal.pgen.1000230.t003
Table 4. Ethosuximide stimulated dauer formation in a low-
density, well-fed population at 27uC.
Genotype Ethosuximide (mg/ml) Dauer (%) N (animals)
WT 0 0 1310
WT 4 9.9*** 1322
osm-3(p802) 0 6.6 637
osm-3(p802) 4 5.0 697
***p,0.0001, comparisons are to the same genotype with no drug treatment. p
values determined by Student T-test.
doi:10.1371/journal.pgen.1000230.t004
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standard culture conditions that do not promote dauer formation,
2 mg/ml ethosuximide treatment enhanced the dauer arrest
phenotype of daf-2(m41) mutants from 3.4 percent (N=263) to
91.3 percent (N=304), suggesting an interaction between
ethosuximide and insulin/IGF-1 signaling.
In addition, the insulin/IGF-1 signaling pathway regulates the
ability of animals that hatch in the absence of food to arrest at the
L1 stage of development [59,60]. Loss-of-function mutations in
daf-2 and age-1 cause animals to arrest at the L1 stage
inappropriately when food is present [55,61]. The activity of
chemosensory neurons modulates this L1 arrest, since mutations in
genes such as osm-3 and che-3 enhance the L1 arrest phenotype of
daf-2 and age-1 mutants [54,61]. To test the effects of ethosuximide
treatment on L1 arrest, we treated daf-2 mutants with the lifespan-
extending dose of 4 mg/ml ethosuximide. Treatment of daf-
2(e1370) animals with ethosuximide significantly increased L1
arrest from 19.2 percent in untreated animals to 47.5 percent in
drug treated animals (Table 5). The ability of mutations that affect
chemosensory neurons to enhance the daf-2 L1 arrest phenotype
requires the activity of daf-16, since the addition of a daf-16
mutation abrogates this effect [62]. Similarly, the daf-16(mu86)
mutation significantly reduced the effect of ethosuximide treat-
ment from 47.5 percent in daf-2(e1370) mutants to 2.3 percent in
daf-2(e1370); daf-16(mu86) mutants (Table 5). These results
indicate that ethosuximide treatment and mutations that disrupt
chemosensory neurons have a similar effect on the L1 arrest
phenotype of an insulin-signaling mutant, consistent with the
model that ethosuximide inhibits the activity of chemosensory
neurons. One interpretation of these findings is that daf-2(e1370)
mutants are hypersensitive to ethosuximide toxicity, since wild-
type animals treated with 12 mg/ml ethosuximide also arrest
development at the L1 stage.
osm-3 Mutants Display an Extended Lifespan and Are
Resistant to the Lifespan Extension Caused by
Ethosuximide
In addition to functioning in chemotaxis, dauer formation, and
L1 larval arrest, chemosensory neurons play a role in adult lifespan
determination [32–34]. The finding that ethosuximide treatment
extends the adult lifespan and affects the activity of chemosensory
neurons, suggests that ethosuximide extends adult lifespan by
affecting the activity of chemosensory neurons. To investigate this
model, we monitored the lifespan of osm-3(p802) hermaphrodites.
osm-3mutantsdisplaya significantlyextendedlifespan[32] (Figure 7
and Table 6). If ethosuximide extends the adult lifespan by
modulating the activity of chemosensory neurons, then osm-3(lf)
animals are predicted to be resistant to the lifespan extension caused
by ethosuximide. Treatment of wild-type hermaphrodites with
2 mg/mlor4 mg/mlethosuximidesignificantlyextended themean
lifespan by 16 percent or 13 percent, respectively, and the
maximum lifespan by 29 percent or 21 percent, respectively
(Figure 7 and Table 6). By contrast, treatment of osm-3(p802)
hermaphrodites with 2 mg/ml or 4 mg/ml ethosuximide did not
cause a statistically significant extension of mean or maximum
lifespan (Figure 7 and Table 6).These results support the model that
ethosuximide extends lifespan by inhibiting chemosensory neurons.
Discussion
Chemosensory Neurons Are the Cellular Target of the
Lifespan-Extending Drug, Ethosuximide
A variety of drugshave beendemonstrated toextend the lifespanof
invertebrates, including compounds that are proposed to act as
antioxidants [4–9], complex chemical mixtures derived from plants
[10,11], resveratrol [12,13], histone deacetylase inhibitors [63,64],
and compounds that influence the vertebrate nervous system [14–
17]. In each case, the understanding of how these drugs act to extend
lifespan is limited. In particular, the cellular target has not been
established for any of these compounds. Advancing this understand-
ing is challenging because of the complexity of the aging phenotype
and the fact that many determinants influence lifespan. Character-
izing the mechanism of these drugs and defining the cellular target of
action is critical for elucidating the endogenous pathways that are
affected by the drugs, and ultimately using these drugs in therapeutic
applications. Here we demonstrate that chemosensory neurons are
the cellular target of ethosuximide in lifespan extension. Two lines of
evidence support this conclusion. First, ethosuximide treatment
Table 5. Ethosuximide enhanced daf-2(e1370) L1 arrest.
Genotype
Ethosuximide
(mg/ml)
L1 arrest
‘
(%) N (animals)
WT 0 0 471
WT 4 0.6 449
daf-2(e1370) 0 19.2 332
daf-2(e1370) 4 47.5*** 284
daf-16(mu86) 0 0 497
daf-16(mu86) 4 2.7*** 558
daf-2(e1370)daf-16(mu86) 0 0.3 603
daf-2(e1370)daf-16(mu86) 4 2.3* 469
‘This value includes arrested L1 larvae and eggs that failed to hatch, as
described by Gems et al. (1998) [55]. Unhatched eggs were only a small
proportion of this total. Statistical comparisons are to the same genotype with
no drug treatment. Numbers with no asterisks are not significant (P.0.05); *,
P,0.05; **, P,0.005; ***, P,0.0001. P values determined by Student T-test.
The 47.5 value in line four is significantly larger than the 2.3 value in line eight
(P,0.0001).
doi:10.1371/journal.pgen.1000230.t005
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Figure 7. osm-3 mutants were long-lived and failed to respond
to lifespan extension by ethosuximide. Wild-type (WT) or osm-
3(p802) hermaphrodites were cultured with 0 mg/ml or with 4 mg/ml
ethosuximide (+ETH 4) from conception until death. Day 0 represents
the L4 stage.
doi:10.1371/journal.pgen.1000230.g007
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in chemosensory neurons, including defective chemotaxis, abnormal
dauer arrest, abnormal L1 arrest and extended lifespan. Second, osm-
3 mutants that are defective in a subset of chemosensory neurons
were resistant to the lifespan extension caused by ethosuximide
treatmentandthe toxiceffectsofethosuximide.Togethertheseresults
suggest that ethosuximide inhibits chemosensory function to extend
C. elegans lifespan. This conclusion is important because it defines a
specific cellular target for a lifespan extending drug and it
demonstrates for the first time that a drug can act on specific cells
in the nervous system to extend lifespan.
Our previous studies of the related compound trimethadione
demonstrated that osm-3 mutants are partially resistant to the mean
lifespan extension caused by trimethadione and are fully resistant to
the maximum lifespan extension cause by trimethadione [14].
These results are consistent with the conclusion that the lifespan
extension caused by trimethadione is partly caused by inhibiting the
function of chemosensory neurons. The finding that part of the
lifespan extending activity of trimethadione was not suppressed by
an osm-3 mutation raises the possibility that trimethadione functions
by additional mechanisms to extend lifespan.
We demonstrated that resistance to ethosuximide lethality can be
caused by mutations in several different genes that disrupt ciliated
neuron structure and function, including che-3, osm-3, che-13, osm-5
and daf-10. Ciliated neurons in the amphid sheath have access to the
environment so that they can detect chemicals and function in
sensory perception. Because these neurons are exposed to the
environment the cell membranes can be stained with lipophilic dyes.
These observations raise the possibility that ciliated neurons absorb
water-soluble chemicals, like ethosuximide, from the environment
and mutations that disrupt cilium structure reduce drug absorption
[24]. However, several lines of evidence suggest that mutants with
defects in ciliated neurons are normal for drug absorption. First, we
demonstrated that che-3(am162) mutants were weakly resistant to
ethosuximide lethality and strongly defective in DiO staining. By
contrast, che-3(am178) mutants raised at 20uC were strongly resistant
to ethosuximide lethality but displayed relatively normal DiO
staining, indicating that the ciliated neurons in these mutants have
access to the environment. The lack of a correlation between dye-
filling defects and ethosuximide resistance suggests that the
ethosuximide resistance of che-3 m u t a n t si sn o tc a u s e db yad e f e c t
in the ability of the drug to enter the animal. Second, we
demonstrated that osm-3 mutants are not resistant to drugs in
general. Cilium structure mutants are resistant to the effects of the
nematicidal drug ivermectin [24]. Therefore, we directly tested the
possibility that cilium structure mutants are resistant to drugs in
general by analyzing sensitivity to a third compound, serotonin. osm-3
mutants and wild-type animals displayed similar sensitivity to egg-
laying stimulation caused by serotonin, indicating that the mutation
does not impair absorption of serotonin. In addition, screens for
mutations that cause resistance to fluoxetine [27,39], levamisole [65],
benzimidazole [66], aldicarb [67], nemadipine-A [41], BMS-192364
[40], and a-amanatin [68] have been described. Despite extensive
screeningandthesuccessfulidentificationofmutantsresistant tothese
compounds, none of these reports describe the isolation of mutations
that disrupt the structure of ciliated neurons. While the failure to
identify a class of mutations in a genetic screen is not a definitive
finding, these results suggest that mutations that disrupt cilium
structure do not cause significant resistance to these compounds.
Third, we took advantage of our observation that ethosuximide
treatment stimulates egg-laying and this effect requires the non-
ciliated HSN neurons [14]. osm-3(p802) mutants that are highly
resistanttothelethalityandlifespanextensioncausedbyethosuximde
were nonetheless sensitive to the egg-laying effects of the drug,
indicating that these mutants are not defective in ethosuximide
absorption. A simple model to explain our findings is that
ethosuximide is absorbed by animals independent of the structure
of ciliated neurons and the drug influences the activity of multiple
neurons throughout the body. The activity of ethosuximide on HSN
neurons that mediate egg-laying is intact in osm-3 mutants whereas
the activity on ciliated neurons that mediate toxicity and lifespan
extension is altered.
Chemosensory Neurons Control Lifespan
Chemosensory neurons have been extensively characterized in
C. elegans to understand behavior, and Kenyon and colleagues
demonstrated that chemosensory neurons play an important role
in controlling adult lifespan [32,34]. Mutants that have defects in
chemosensory neuron function display an extended lifespan [32],
and ablation of specific neurons such as ASI, AWA, and AWC
extends the adult lifespan [34]. Here we provide an independent
line of evidence that these neurons control lifespan. Our results
indicate that ethosuximide inhibits the activity of chemosensory
neurons and thereby causes a lifespan extension. These results
provide independent support the model that high levels of
chemosensory neuronal activity promote a reduced lifespan and
inhibiting these neurons causes a lifespan extension.
Animportantissue thatisraisedbytheseobservationsishowdoes
the activity of chemosensory neurons influence lifespan? One
possibility is that the chemosensory neurons regulate the activity of
the insulin/IGF-1 signaling pathway. Amphid neurons are the site
of expression of many insulin/IGF-1 ligands [69] raising the
possibility that these neurons release ligand in response to
environmental cues and thereby influence lifespan by an endocrine
Table 6. osm-3 mutants displayed an extended lifespan and were resistant to the lifespan extension caused by ethosuximide.
Genotype
Ethosuximide
(mg/ml)
Mean Lifespan6SD
(days)
Percent
Change
‘ p
‘
Maximum Lifespan6SD
(days)
#
Percent
Change
‘ p
‘ N*
WT 0 18.763.7 - - 24.961.3 - - 164
2 21.766.7 +16 ,0.0001 32.262.4 +29.3 ,0.0001 146
4 21.265.6 +13.4 ,0.0001 30.262.0 +21.3 ,0.0001 158
osm-3(p802) 0 22.566.4 - - 34.464.3 - - 128
2 23.967.0 +6.2 0.10 35.663.6 +3.5 0.44 131
4 22.166.2 21.8 0.65 35.064.0 +1.7 0.71 122
‘Comparisons are to the same genotype with no drug treatment. p values determined by Student T- test.
#Maximum adult lifespan is the mean lifespan of the 10% of the population that had the longest lifespan.
*Number of animals observed in three independent trials.
doi:10.1371/journal.pgen.1000230.t006
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arrest in daf-2 mutants, similar to osm-3 mutations [54,61]. An
important test of this model is the dependence of these effects on
DAF-16, a transcription factor that mediates effects of insulin/IGF-
1 signaling. Ethosuximide enhancement of L1 arrest was dramat-
ically reduced by a daf-16(lf) mutation. Furthermore, ablation of
ASI amphid neurons extends lifespan in a manner the requires the
DAF-16 FOXO transcription factor [34]. These results suggest that
amphid neurons are important for insulin/IGF-1 signaling and that
ethosuximide may extend lifespan by disrupting this pathway.
However, ethosuximide and osm-3 mutations extend the lifespan of
daf-16 mutants, indicating loss of insulin/IGF-1 signaling cannot
fully explain these lifespan extensions [14,32]. Furthermore,
ablation of AWA and AWC amphid neurons extends the lifespan
of daf-16 mutants [34]. Therefore, our data support the model that
ethosuximide acts through insulin-dependent and insulin-indepen-
dent pathways to extend C. elegans lifespan.
Sensory Perception of Food May Accelerate Lifespan, and
Inhibition of Sensory Perception May Be Sufficient to
Extend Lifespan
Restricting dietary intake can extend lifespan in many animal
models[70–73],andtheseobservationsdocumentthecriticalrole of
food availability in controlling lifespan. An important question is
how do animals assess food availability to control lifespan? In
particular, is food availability determined metabolically, by
monitoring nutrients that are ingested, or is food availability
determined by neural sensation, by monitoring food derived cues in
the environment? Recent studies in Drosophila indicate that the
effects of dietary restriction are mediated, in part, by the perception
of food-derived cues [74]. Exposure of flies to food-derived odors
can partially suppress the lifespan extension caused by dietary
restriction. Therefore, mutations that extend lifespan by disrupting
chemosensationmay block perception of food-related chemical cues
and thereby activate pathways that respond to dietary restriction.
Here we demonstrate that the anticonvulsant ethosuximide
extends C. elegans lifespan by inhibiting sensory neurons that are
hypothesized to mediate attraction to environmental food sources.
Hermaphrodites treated with ethosuximide appear to ingest a
normal amount of food since they do not display a diminished
body size or progeny production, the characteristics of dietary
restricted animals [72]. These results suggest that inhibiting the
sensation of food is sufficient to extend lifespan even in the
presence of normal food ingestion. These observations raise the
exciting possibility that inhibiting the sensation of food may be a
conserved mechanism of lifespan extension. In addition to
controlling seizures, a common side effect of ethosuximide
treatment in humans is loss of taste sensation [75]. Therefore,
targeting sensory mediated processes with drugs like ethosuximide
may present a means to extend mammalian lifespan.
Materials and Methods
General Strains and Methods
C. elegans strains were cultured at 20uC on 6 cm Petri dishes
containing nematode growth media (NGM) agar and a lawn of E.
coli strain OP50 unless otherwise noted [76]. Unless otherwise
noted, preparation and storage of dishes containing pharmaco-
logical compounds was performed as previously described [14].
We used the following C. elegans mutations that are described in
Riddle et al. [23] or in this study: che-3(e1124) I, che-3(am165) I, che-
3(am162) I, che-3(am178) I, che-13(e1805) I, daf-16(mu86) I, unc-
11(e47) I, dpy-5(e61) I, unc-29(e1072) I, unc-75(e950) I, daf-2(e1370)
III, daf-2(m41) III, osm-3(p802) IV, osm-3(am161) IV, osm-3(am177)
IV, osm-3(am172) IV, daf-10(e1387) IV, osm-5(p813) X, lin-
15(n765) X, cca-1(ad1650) X, and cca-1(gk30) X.
The following well-characterized mutations were used in this
study: che-3(e1124 Q2233stop) is a probable null mutation in the
CHE-3 dynein [42]; che-13(e1805 Q219stop) is a loss-of-function
mutation that affects the IFT57 protein [77]; osm-3(p802 Q346stop)
is a strong loss-of-function mutation that disrupts the OSM-3
kinesin [47]; daf-10(e1387 Q892stop) is a loss-of-function mutation
that disrupts the IFT122 protein [78]; osm-5(p813 Q473stop) is a
loss-of-function mutation that disrupts the Tg737/Polaris protein
[79]; daf-2(e1370 P1465S) is a partial loss-of-function mutation that
affects the kinase domain of the DAF-2 receptor tyrosine kinase
[56]; daf-2(m41 G383E) is a weak loss-of-function mutation that
affects the ligand-binding domain of the DAF-2 receptor tyrosine
kinase [80]; daf-16(mu86) is a probable null mutation that results in
deletion of most of the DAF-16 coding sequence including all of
the forkhead domain [57]; cca-1(ad1650) and cca-1(gk30) are strong
loss-of-function mutations that result in deletions of different
portions of the CCA-1 coding sequence [37].
Isolation and Genetic Analysis of Ethosuximide-Resistant
Mutants
N2 hermaphrodites (P0) were mutagenized as described by
Brenner [76] with either 50 mM EMS or 0.5 mM ENU. 100,000
F1 hermaphrodites were treated with hypochlorite, and F2 eggs
were plated on NGM containing 10–12 mg/ml ethosuximide
(Sigma, St. Louis, MO). Since E. coli failed to form a thick lawn on
dishes containing 12 mg/ml ethosuximide, these dishes were
seeded with E. coli OP50 that had been concentrated 10-fold. F2
progeny that matured to the L4/adult stage were picked as
ethosuximide resistant mutants, and populations derived from
these individuals were retested for ethosuximide resistance. 48
independently derived ethosuximide resistant mutants were
isolated. These mutant strains were backcrossed at least twice to
wild-type (N2) to remove extraneous mutations. Forty-two mutant
strains were backcrossed successfully, indicating that ethosuximide
resistance was caused by a single mutation.
Positioning Mutations Relative to SNP Markers and
Visible Markers
Single nucleotide polymorphism (SNP) mapping analysis was
performed on a subset of resistant mutants by mating ethosuximide
resistant mutants (P0) to the divergent CB4856 strain (P0), selecting
F1 outcross progeny, and scoring F2 self-progeny for ethosuximide
resistance. F2 animals that displayed resistance were judged to be
homozygous for the mutation, and F3 progeny were harvested for
DNA. SNPs distributed throughout the C. elegans genome [81] were
scored using Pyrosequencing (Biotage Foxboro, MA) or direct DNA
sequencing.Linkagevalueswerecalculatedbydeterminingtheratio
of N2 DNA to CB4856 DNA at each polymorphism.
The am178 mutation was tightly linked to a SNP marker at the
center of Chromosome I. Three factor mapping experiments with
visible markers yielded the following results. From am178/unc-11 dpy-
5 hermaphrodites, 5/6 Unc non Dpy self progeny segregated am178
and 0/9 Dpy non Unc self progeny segregated am178;F r o mam178/
dpy-5 unc-75 hermaphrodites, 3/8 Unc non Dpy self progeny
segregated am178; From am178/dpy-5 unc-29 hermaphrodites, 7/8
Dpy non Unc self progeny segregated am178. These results position
am178 right of dpy-5,l e f to func-75, and probably left of unc-29.
For high resolution SNP mapping of am178, we mated dpy-
5(e61) am178 and am178 unc-75(e950) homozygotes to CB4856
males, picked F1 outcross progeny, and selected non-Dpy and
non-Unc F2 self-progeny resistant to 12 mg/ml ethosuximide. We
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chromosome and scored SNP markers.
Complementation and Transgenic Rescue
Because che-3 and osm-3 mutations interfere with male mating,
che-3(e1124) and osm-3(p802) were maintained over hT2 and nT1
myo-2::GFP balancer chromosomes, respectively. For complemen-
tation analysis with am178 and che-3(e1124), one am178 hermaph-
rodite was mated to five che-3(e1124)/hT2 males and outcross
progeny were scored for ethosuximide resistance. Non-GFP,
outcrossed am178/che-3(e1124) animals survived 12 mg/ml etho-
suximide treatment, indicating that che-3(e1124) and am178 fail to
complement for ethosuximide resistance. Neither che-3(e1124)/+
nor am178/+ animals survived 12 mg/ml ethosuximide treatment.
For complementation analysis with dye-filling defective alleles,
ethosuximide resistant mutants that displayed a Dyf phenotype
were mated to either che-3(e1124)/hT2 or osm-3(p802)/nT1 males,
and non-GFP outcross progeny were subjected to dye-filling
analysis. 9/9 am172/osm-3(p802) animals, 15/15 am177/osm-
3(p802) animals and 20/25 am161/osm-3(p802) animals displayed
a Dyf phenotype, indicating that these three alleles fail to
complement osm-3(p802) for dye-filling. 14/15 am165/ che-
3(e1124) animals and 9/9 am162/ che-3(e1124) animals displayed
a Dyf phenotype, indicating that these two alleles fail to
complement che-3(e1124) for dye-filling.
To analyze the ability of genomic DNA to rescue the mutant
phenotype of am178, we generated transgenic animals containing
extrachromosomal arrays using standard procedures [82]. Fosmid
clone WRM0637cB0 contains the entire che-3 coding region and
only one other entire gene, F18C12.4. To identify transgenic
animals, we co-injected the fosmid clone WRM062bF09 that
rescues the lin-15(n765) multi-vulval (Muv) phenotype (M. Nonet,
personal communication). These two fosmids were co-injected at a
concentration of 20 ng/ml each into am178; lin-15(n765ts) animals
to generate the transgenic array amEx100. Hermaphrodites
containing the amEx100 array transmitted it to about 73% of
self-progeny, since 27% of self-progeny were Muv (n=100). When
self-progeny of am178; lin-15(n765);amEx100 hermaphrodites were
plated on media containing 12 mg/ml ethosuximide, the only
animals that survived to adulthood after 5–6 days were Muv
(N=59), indicating that they did not contain amEx100. These
results indicate that the amEx100 array rescues the am178
resistance to ethosuximide phenotype, suggesting that the gene
affected by am178 is contained in fosmid WRM0637cB0.
DNA Sequence Analysis and RNA Analysis
DNA sequencing was performed using standard procedures. We
PCRamplified predicted exonsandsplicejunctions(www.wormbase.
org) from the che-3 and osm-3 genes using DNA from am178 and
am177 mutant animals, respectively. The am178 strain contained a G
to A change at the fifth base of intron 9. To analyze the che-3
messenger RNA, we prepared RNA from a population of am178
mutants (TRizol, Invitrogen), DNase treated the RNA (DNA-free,
Ambion), and generated cDNA by performing reverse transcription
(Retroscript, Ambion). We PCR amplified the junctions between
exons 9 and 10 and determined the DNA sequence of the PCR
product to infer the splicing pattern of the mRNA. The che-3 mRNA
derived from am178 mutants displayed a deletion of 17 nucleotides
(GTCAGCTTGGTTTTTGC) in exon 9.
Dye-Filling Analysis
Staining with DiO was performed using previously described
methods [31,83]. L4 hermaphrodites were placed in 100 mLo fM 9
buffer containing 20 mg/ml DiO (Molecular Probes) in a microtiter
dish and incubated for ,2 hrs at room temperature. To remove
non-specifically bound DiO, we transferred the animals to a NGM
dish seeded with E. coli OP50 and cultured for 20–30 minutes at
room temperature. For analysis of strains in Table 1, five to fifteen
animals were observed using a Zeiss Axioplan 2 microscope
equipped for fluorescence microscopy at 4006 magnification.
Animals were categorized in the following classes: (I) No amphid
neurons stained; (II) 1–2 amphid neurons stained; or (III) more than
2 amphid neurons stained. All the strains described in Table 1
displayed only the class I or only the class III pattern of staining. For
analysis of che-3(am178) mutants in Table 2, DiO staining was
observed using an Olympus SZX12 dissectingmicroscopeequipped
for fluorescence microscopy at 1446magnification. Animals were
scored as Dyf if no amphid neurons stained robustly with DiO.
Quantification of Ethosuximide Resistance
To quantify the penetrance of the ethosuximide resistance
phenotype, we adapted an assay method described by Rand and
Johnson [84]. Eggs were picked to a Petri dish with agar containing
12 mg/ml ethosuximide and counted. Five to six days later we
counted the number of animals that matured past the L1 stage. For
resistant strains most animals were L4 larvae or adults. The
remaining eggs produced animals that did not mature past the L1
stage or left the agar surface. The number of animals that matured
past the L1 stage was divided by the total number of eggs to
determine the percent resistant to ethosuximide.
Chemotaxis to Volatile Compounds
For pharmacological analysis of chemotaxis, dishes were prepared
by adding powdered ethosuximide directly to 60uC chemotaxis agar,
agitating to dissolve the compound and dispensing to 10 cM Petri
dishes. Chemotaxis assays were performed as described previously
[85] with two minor modifications. First, to obtain a large number of
well-fed animals for the assay, we cultured animals from conception
to adulthood in the presence of ethosuximide or no drug on 6 cM
Petri dishes containing OP50 that was concentrated 10-fold. Second,
we added ethosuximide to the molten chemotaxis agar before
dispensing into 10 cM Petri dishes and used these dishes after 3–
8 hours. To conductchemotaxis assays,we pipeted animals in a small
volume of liquid onto the center of a 10 cM Petri dish that had been
pre-treated with 1 mLo f1 MN aa z i d e ,ap a r a l y z i n ga g e n t ,a tt w o
diametrically opposed spots on the plate. At this time, we added 1 mL
of volatile odorant to one azide treated spot and 1 mL of ethanol as a
control to the other azide treated spot. Isoamyl alcohol and diacetyl
were diluted in ethanol at concentrations of 1:10 and 1:1000,
respectively. After 60 minutes we scored the number of paralyzed
animals at each azide spot and the number of moving animals on the
plate. The sodium azide spots were positioned at the edge of the dish,
and animals that desiccated on the side of the dish at the positions of
the sodium azide spots were attributed to those categories; otherwise
such animals were attributed to the moving animal category.
Chemotaxis index was determined using the following formula:
Number of animals at odorant ðÞ { Number of animals at ethanol ðÞ
Total number of animals on plate
Analysis of Egg-Laying
The analysis of egg-laying was performed as described
previously [85]. To determine the effect of ethosuximide on egg-
laying, we picked L4 hermaphrodites, incubated them at 20uC for
approximately 20 hours on NGM plates with abundant food,
individually placed them in 100 mL of M9 buffer in a microtiter
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laid in 90 minutes. We used a similar method to analyze serotonin,
except animals were placed in 50 mL buffer.
Analysis of Dauer Larvae and Larval Arrest Phenotypes
To analyze dauer formation at 27uC, we allowed 8–10 gravid
hermaphrodites to lay eggs on one Petri dish for 4–8 hours at
room temperature and then incubated the dish at 27uC for
precisely 44 hours [52]. We counted the total number of animals
on the dish, flooded the dish with 1% SDS to kill all animals
except for dauer larvae, and counted the number of live dauer
larvae after 15 minutes. To analyze dauer formation at 25uC, we
prepared NGM media without peptone, the main carbon source
for the E. coli OP50. The omission of peptone from the media
allowed us to provide a consistent amount of E. coli OP50 food,
and made the experiment independent of the effects of
ethosuximide on bacterial proliferation. We aliquoted 200 mlo f
an overnight E. coli OP50 culture that had been concentrated 10-
fold on each dish. We placed two L4 hermaphrodites on each dish,
incubated the animals at 25uC, and monitored the dishes daily for
starvation [86]. Five days post-starvation we scored the number of
dauer larvae by flooding the dishes with 1% SDS and counting the
number of live animals after 15 minutes. Dauer formation of daf-
2(m41) mutants was analyzed as described previously [16].
To analyze the L1 arrest phenotype, we cultured L4
hermaphrodites 1–2 days on NGM dishes with 4 mg/ml
ethosuximide or no drug, transferred these adults to fresh dishes
with 4 mg/ml ethosuximide or no drug for 4–8 hours at room
temperature, and removed the adults. These dishes containing
freshly deposited eggs were cultured at 25.5uC for 48 hours. We
counted the number of eggs, L1 larvae, and older larval stages.
Lifespan Analysis
For a typical lifespan experiment, parental worms were cultured
in the presence of the drug, and progeny were selected at the L4
stage for lifespan analysis. Thus, these progeny were exposed to
drug from the time of conception until death. For measurements of
lifespan, hermaphrodites were chosen for analysis at the L4 stage
(defined as day 0) and analyzed every 1–2 days from day 3 until
death. Approximately 15 hermaphrodites were cultured on each
Petri dish. Hermaphrodites were transferred to fresh Petri dishes
about every two days until the cessation of progeny production
and about every week thereafter. Animals were scored as dead if
they displayed no spontaneous movement or response when
prodded. Dead worms that displayed internally hatched progeny,
an extruded gonad or desiccation due to crawling off the agar were
excluded from the data. Lifespan is the number of days from the
L4 stage to the average of the last day a worm was observed to be
alive and the first day a worm was observed to be dead. Lifespan
experiments involving pharmacological compounds were always
done in parallel with a control group.
Statistical Methods
For each experimental group, comparisons were made to a
control group maintained in the same incubator and analyzed at
the same time points. Mean, standard error, P values, and other
statistical parameters were calculated using InStat 2.03 software
(Graphpad Software) or Microsoft Excel.
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